Modality
Degrader
MOA
FcRni
Target
FLT3
Pathway
PD-1/PD-L1
PTSD
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
~Jul 2023
→ ~Oct 2024
NDA/BLA
Jan 2025
→ Jun 2026
NDA/BLACurrent
NCT06342263
1,608 pts·PTSD
2025-01→2026-06·Recruiting
1,608 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-102mo awayPh3 Readout· PTSD
Trial Timeline
2025Q2Q3Q42026Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-06-10 · 2mo away
PTSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06342263 | NDA/BLA | PTSD | Recruiting | 1608 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 |